Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial

Noorbala, Ahmad-Ali; Hosseini, Seyed Hamzeh; Mohammadi, Mohammad Reza; Akhondzadeh, Shahin

doi:10.1046/j.1365-2710.1998.00156.x

Cited by 6 publications

(1 citation statement)

References 19 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some authors have questioned whether the power of noradrenaline reuptake inhibition induced by venlafaxine is equal to that induced by clomipramine (Gillman, 2007). In addition, although noradrenaline reuptake inhibition alone does not seem to promote OCD symptom improvement (Hoehn-Saric, et al, 2000), it remains possible, albeit unproven, that the combination of noradrenaline reuptake inhibition and serotonin reuptake inhibition has a synergistic effect (Noorbala, et al, 1998;Fontenelle, et al, 2005). The pharmacokinetic hypothesis would suggest that efficacy is associated with increased serum levels of clomipramine in relation to its metabolite (N-desmethylclomipramine) due to cytochrome P450 saturation induced by some SSRI.…”

Section: Discussionmentioning

confidence: 99%

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial

et al. 2009

View full text Add to dashboard Cite

After 12 weeks of selective serotonin reuptake inhibitor (SSRI) monotherapy with inadequate response, 10 patients received clomipramine and 11 received quetiapine as augmentation agents of the SSRI. The primary outcome measure was the difference between initial and final scores of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), rated in a blinded fashion, and the score of clinical global improvement (CGI-I). Statistical analyses were performed using nonparametric tests to evaluate treatment efficacy and the difference between treatment groups. Percentile plots were constructed with YBOCS scores from the clomipramine and quetiapine groups. Considering response a >or=35% reduction in the initial Y-BOCS score plus a rating of 'much improved' or 'very much improved' on CGI-I, four of eleven quetiapine patients and one out of ten clomipramine patients were classified as responders. The mean final Y-BOCS score was significantly lower than baseline in the quetiapine augmentation group (P = 0.023), but not in the clomipramine augmentation group (P = 0.503). The difference between groups showed a trend towards significance only at week 4, the mean Y-BOCS score being lower for those receiving quetiapine (P = 0.052). A difference between groups was also observed at week 4 according to percentile plots. These results corroborate previous findings of quetiapine augmentation efficacy in obsessive-compulsive disorder (OCD). Clomipramine augmentation did not produce a significant reduction in Y-BOCS scores. Higher target maximum dosages might have yielded different results.

show abstract

Section: Discussionmentioning

confidence: 99%

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial

et al. 2009

View full text Add to dashboard Cite

show abstract

Neurobiology and Pharmacotherapy of Obsessive‐Compulsive Disorder

Rapoport

Inoff‐Germain

2007

Handbook of Contemporary Neuropharmacology

View full text Add to dashboard Cite

Obsessive‐compulsive disorder (OCD) is characterized by the presence of unwanted, senseless, intrusive and distressing thoughts, urges and images (obsessions) and/or repetitive behaviors (compulsions). While classified as an anxiety disorder in DSM‐IV, OCD is given a separate chapter here as the clinical phenomenology, drug treatment response, family studies, and brain imaging data support a separate neurobiological classification for this disorder and a distinct neuropharmacologic profile as well. Our current understanding of its underlying neurobiology as well as the state of treatment for OCD is provided through a selective review of OCD‐related (1) brain imaging studies, (2) genetic studies, (3) animal models, (4) psychopharmacology, including immunomodulatory treatment, and (5) experimental non‐pharmacological treatments such as neurosurgery, transcranial magnetic stimulation, and deep brain stimulation.

show abstract

Polypharmazie in der Behandlung von Angst- und Zwangsstörungen

Volz¹

2006

Polypharmazie in Der Behandlung Psychischer Erkrankungen

View full text Add to dashboard Cite

Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial

Abstract: As this study indicates, a rapid onset of action is one of the advantages of this combination. This study supports further investigation of the noradrenergic-serotonergic hypothesis in OCD.

Cited by 6 publications

References 19 publications

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial

Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial

Neurobiology and Pharmacotherapy of Obsessive‐Compulsive Disorder

Polypharmazie in der Behandlung von Angst- und Zwangsstörungen

Contact Info

Product

Resources

About